ESTRO 2024 - Abstract Book

S2361

Clinical - Urology

ESTRO 2024

Results:

29 post-prostatectomy pts (Adjuavnt, n=2; Salvage, n=27) were finally included and treated by MRgRT. Patient characteristics were shown in Table.1.. All fractions were successfully delivered without interruption (median duration: 38 minutes; range: 22-46 minutes), with 96% of ATP and 4% of ATS. The median follow-up duration was 20.4 months (range: 3 - 42 months). All pts had their PSA levels below 0.05ng/ml within 1-month. Regarding toxicity, no acute ≥G2 adverse event (≤3 months) was scored (0%), and 2 late G2 events (rectal bleeding and urinary frequency) were scored in two pts (6.9%). There were no G3 or above events during the entire follow-up. Two pts had biochemical recurrence (PSA≥0.2ng/ml) after MRgRT at month -28 (patient A) and month-30 (patient B), respectively. Patient A (pT3aN0M0; ISUP grade group: 5; pre-MRgRT PSA: 0.37ng/ml) was also detected with local recurrence by PSMA-PET at month-28. No patients developed distant metastasis at this point. The estimated bPFS was 100% at 24-month and 75% (95%CI: 50.3%-100%) at 36-month, and rPFS 100% at 24-month and 87.5% (95%CI: 67.3%-100%) at 36-month, respectively.